Lung cancer vaccine enters the lab

A vaccine has moved into a Phase I trial for patients with non-small cell lung cancer (NSCLC) in a collaboration between Californian biotech Asterias Biotherapeutics (NYSE American:AST) and the charity Cancer Research UK.

The UK charity will manage the initial clinical development of AST-VAC2, a promising immunotherapy candidate derived from a standardized human embryonic stem cell line, which was brought to the charity through its Clinical Development Partnerships scheme.

"With its potential to be used off-the-shelf, AST-VAC2 is an exciting development in the rapidly evolving field of immunotherapy"